

# Alexander Gerhard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6258057/publications.pdf>

Version: 2024-02-01

44  
papers

3,282  
citations

331670

21  
h-index

254184

43  
g-index

46  
all docs

46  
docs citations

46  
times ranked

4861  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	1.9	7
2	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 336-339.	1.9	1
3	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
4	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum $\tau$ and $\text{pNfH}$ : A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
5	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
6	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	2.6	3
7	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
8	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. <i>Journal of Neurology</i> , 2022, 269, 4322-4332.	3.6	1
9	The $\text{CBlâ€R}$ detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	3.7	1
10	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i> -associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771.	1.9	12
11	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.1	5
12	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.8	36
13	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.8	31
14	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
15	Does increased microglial activation lead to faster progression in PSP?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 685-685.	1.9	1
16	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
17	Altered network stability in progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2021, 107, 109-117.	3.1	8
18	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28

#	ARTICLE	IF	CITATIONS
19	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	10.8	9
20	A data-driven disease progression model of fluid biomarkers in genetic FTD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
21	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
22	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020, 77, 377.	9.0	94
23	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	175
24	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984.	1.9	25
25	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-26.	0.7	5
26	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2831-2847.	6.4	45
27	Widespread microglial activation in multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 564-568.	3.9	41
28	Microglial activation, white matter tract damage, and disability in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e443.	6.0	51
29	Functional neuroanatomical associations of working memory in early-onset Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 176-184.	2.7	10
30	Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2018, 83, 61-69.	1.3	266
31	Frontotemporal lobar degeneration and social behaviour: Dissociation between the knowledge of its consequences and its conceptual meaning. <i>Cortex</i> , 2017, 93, 107-118.	2.4	22
32	TSPO imaging in parkinsonian disorders. <i>Clinical and Translational Imaging</i> , 2016, 4, 183-190.	2.1	56
33	<sup>18</sup> F-GE-180: a novel TSPO radiotracer compared to <sup>11</sup> C-R-PK11195 in a preclinical model of stroke. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 503-511.	6.4	109
34	[ <sup>11</sup> C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1406-1419.	6.4	55
35	Imaging of Neuroinflammation in Parkinsonian Syndromes with Positron Emission Tomography. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 405.	4.2	8
36	Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 527-532.	2.2	18

#	ARTICLE	IF	CITATIONS
37	Brain inflammation is induced by co-morbidities and risk factors for stroke. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1113-1122.	4.1	173
38	Minocycline 1-year therapy in multiple system atrophy: Effect on clinical symptoms and [ <sup>11</sup> C](R)-PK11195 PET (MEMSA trial). <i>Movement Disorders</i> , 2010, 25, 97-107.	3.9	163
39	Reference and target region modeling of [11C](R)-PK11195 brain studies. <i>Journal of Nuclear Medicine</i> , 2007, 48, 158-67.	5.0	216
40	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. <i>Neurobiology of Disease</i> , 2006, 21, 404-412.	4.4	982
41	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. <i>Movement Disorders</i> , 2006, 21, 89-93.	3.9	162
42	Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. <i>NeuroImage</i> , 2005, 24, 591-595.	4.2	235
43	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S591-S591.	4.3	1
44	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. <i>Movement Disorders</i> , 2004, 19, 1221-1226.	3.9	128